PHILADELPHIA--(Revitas, the leader in Enterprise Revenue Dynamics (ERD), today announced the release of Revitas™ Pricing Dynamics v 7.7, designed to help organizations in pharmaceuticals, manufacturing, technology, and other industries manage the strategic pricing initiatives and rebating scenarios that drive sales growth and profitability. Through expanded rebating functionality, the Revitas Pricing Dynamics solution (called Revitas CARS in the pharmaceutical industry) offers businesses increased flexibility to structure rebates and pricing incentives with the assurance that such incentives will be accurately executed. As a result, organizations can better control revenue and drive profitability in highly competitive and often tightly regulated markets.)--
“The risks of errors and lost revenue can have significant consequences in these highly competitive industries. The latest version of the Revitas Pricing Dynamics solution provides organizations more agility in their rebating strategies to protect profit margins and expand market share.”
“The ability to creatively tailor pricing incentive agreements to increase market share is an essential element of the successful sales organization, especially in the pharmaceutical industry,” said Eric Newmark, Program Director of Life Science Business Systems at IDC Health Insights. “Unfortunately, however, many companies are limited in how creative they can be because they don’t have the means to measure and execute on those agreements.”
The Revitas Pricing Dynamics engine is a powerful solution for the determination, management, and execution of contract pricing terms and complex incentive pricing scenarios. The new rebating functionality allows customers to be more creative and agile with their sales strategies, opening up new opportunities to grow market share with confidence that the incentives will be calculated and paid accurately. These capabilities meet the market requirements of companies in the pharmaceutical, manufacturing, and technology industries, where margins are often thin and competitive pressure intense. In particular, generic pharmaceutical manufacturers require dynamic rebating strategies to expand revenue and drive growth.
“As a growth company, it is critical for our continued success to have a solution that permits flexible and creative rebating strategies that drive profitability,” said Paul Dutra, Executive Vice President at Glenmark Generics, Inc., USA. “Equally important for us is that the solution then accurately executes those incentives so that we don't risk losing money and undercut our strategic efforts.”
“When pharmaceutical, manufacturing, and technology companies are implementing complex, multi-tier pricing incentives, manual systems jeopardize their bottom line,” said Al Smith, President and Chief Operating Officer at Revitas. “The risks of errors and lost revenue can have significant consequences in these highly competitive industries. The latest version of the Revitas Pricing Dynamics solution provides organizations more agility in their rebating strategies to protect profit margins and expand market share.”
For more information on Revitas Pricing Dynamics, please visit the Revitas website.
Revitas, the leader in Enterprise Revenue Dynamics, delivers integrated solutions for contracts, pricing, and compliance that drive higher profitability and lower risk. Revitas empowers companies to optimize contract performance by defining, managing, and analyzing complex, multi-tier pricing incentives and enables positive proof of compliance with commercial, financial, and industry requirements. Powered by the secure, scalable, and standards-based Flex™ platform, Revitas™ applications speed time to market and improve visibility across B2B relationships. Hundreds of organizations across the most highly regulated and challenging industries leverage Revitas integrated solutions to save money, make money, and reduce risk. For details, visit www.revitasinc.com or http://blog.revitasinc.com/.